Exploring PI3Kδ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials

References

• Dy R, Sethi S. The lung microbiome and exacerbations of COPD. Curr Opin Pulm Med. 2016;22:196–202. doi:10.1097/MCP.0000000000000268
   PubMed Web of Science ®Google Scholar
• Ritchie AI, Wedzicha JA. Definition, causes, pathogenesis, and consequences of chronic obstructive pulmonary disease exacerbations. Clin Chest Med. 2020;41:421–438. doi:10.1016/j.ccm.2020.06.007
   PubMed Web of Science ®Google Scholar
• Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–671. doi:10.1164/rccm.201104-0597OC
   PubMed Web of Science ®Google Scholar
• Wilkinson TMA, Aris E, Bourne SC, et al. Drivers of year-to-year variation in exacerbation frequency of COPD: analysis of the AERIS cohort. ERJ Open Res. 2019;5:00248–2018. doi:10.1183/23120541.00248-2018
   PubMedGoogle Scholar
• AERIS Study Group; Wilkinson TMA, Aris E, Bourne S, et al. A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD. Thorax. 2017;72:919–927. doi:10.1136/thoraxjnl-2016-209023
   PubMed Web of Science ®Google Scholar
• Liu J, Pang Z, Wang G, et al. Advanced role of neutrophils in common respiratory diseases. J Immunol Res. 2017;2017:6710278. doi:10.1155/2017/6710278
   PubMed Web of Science ®Google Scholar
• Sapey M, Rijkers GT, van Overveld FJ. Neutrophils and emerging targets for treatment in chronic obstructive pulmonary disease. Expert Rev Clin Immunol. 2013;9:1055–1068. doi:10.1586/1744666X.2013.851347
   PubMed Web of Science ®Google Scholar
• Sapey E, Stockley JA, Greenwood H, et al. Behavioral and structural differences in migrating peripheral neutrophils from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183:1176–1186. doi:10.1164/rccm.201008-1285OC
   PubMed Web of Science ®Google Scholar
• Milara J, Lluch J, Almudever P, Freire J, Xiaozhong Q, Cortijo J. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134:314–322. doi:10.1016/j.jaci.2014.02.001
   PubMed Web of Science ®Google Scholar
• To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182:897–904. doi:10.1164/rccm.200906-0937OC
   PubMed Web of Science ®Google Scholar
• Stark A-K, Sriskantharajah S, Hessel EM, Okkenhaug K. PI3K inhibitors in inflammation, autoimmunity and cancer. Curr Opin Pharmacol. 2015;2382–2391.
   Web of Science ®Google Scholar
• Gupta V, Singh D. Critical assessment of the value of sputum neutrophils. COPD. 2013;10:107–114. doi:10.3109/15412555.2013.766105
   PubMedGoogle Scholar
• Tregay N, Begg M, Cahn A, et al. Use of autologous 99mTechnetium-labelled neutrophils to quantify lung neutrophil clearance in COPD. Thorax. 2019;74:659–666. doi:10.1136/thoraxjnl-2018-212509
   PubMed Web of Science ®Google Scholar
• Sims P, Coffman RL, Hessel EM. Biomarkers measuring the activity of Toll-like receptor ligands in clinical development programs. Methods Mol Biol. 2009;517:415–440.
   PubMedGoogle Scholar
• Gauvreau GM, Hessel EM, Boulet LP, Coffman RL, O’Byrne PM. Immunostimulatory sequences regulate interferon-inducible genes but not allergic airway responses. Am J Respir Crit Care Med. 2006;174:15–20. doi:10.1164/rccm.200601-057OC
   PubMed Web of Science ®Google Scholar
• Govoni M, Bassi M, Vezzoli S, et al. Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis. Respir Res. 2020;21:72. doi:10.1186/s12931-020-1329-y
   PubMed Web of Science ®Google Scholar
• Begg M, Wilson R, Hamblin JN, et al. Relationship between pharmacokinetics and pharmacodynamic responses in healthy smokers informs a once-daily dosing regimen for nemiralisib. J Pharmacol Exp Ther. 2019;369:337–344. doi:10.1124/jpet.118.255109
   PubMed Web of Science ®Google Scholar
• Cahn A, Hamblin JN, Begg M, et al. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD. Pulm Pharmacol Ther. 2017;46:69–77. doi:10.1016/j.pupt.2017.08.008
   PubMed Web of Science ®Google Scholar
• van Geffen WH, Hajian B, Vos W, et al. Functional respiratory imaging: heterogeneity of acute exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2018;13:1783–1792. doi:10.2147/COPD.S152463
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). From the global strategy for the diagnosis, management and prevention of COPD; 2020. Available from: http://goldcopd.org. Accessed May 6, 2021.
   Google Scholar
• Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European community for steel and coal. Official statement of the European Respiratory Society. Eur Respir J. 1993;6(suppl 16):5–40. doi:10.1183/09041950.005s1693
   PubMed Web of Science ®Google Scholar
• Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613. doi:10.1164/ajrccm.161.5.9908022
   PubMed Web of Science ®Google Scholar
• Juss JK, House D, Amour A, et al. Acute respiratory distress syndrome neutrophils have a distinct phenotype and are resistant to phosphoinositide 3-kinase inhibition. Am J Respir Crit Care Med. 2016;194(8):961–973. doi:10.1164/rccm.201509-1818OC
   PubMed Web of Science ®Google Scholar
• Vlahos R, Wark PA, Anderson GP, Bozinovski S. Glucocorticosteroids differentially regulate MMP-9 and neutrophil elastase in COPD. PLoS One. 2012;7:e33277. doi:10.1371/journal.pone.0033277
   PubMed Web of Science ®Google Scholar
• Cahn A, Hamblin JN, Robertson J, et al. An inhaled PI3δ inhibitor improves recovery in acutely exacerbating COPD patients, a randomized trial. Int J Chron Obstruct Pulmon Dis. In press 2021.
   Google Scholar
• Butler CC, Gillespie D, White P, et al. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med. 2019;381:111–120. doi:10.1056/NEJMoa1803185
   PubMed Web of Science ®Google Scholar
• ECLIPSE investigators; Vestbo J, Anderson W, Coxson HO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31:869–873. doi:10.1183/09031936.00111707
   PubMed Web of Science ®Google Scholar
• Reinhold D, Morrow JD, Jacobson S, et al. Meta-analysis of peripheral blood gene expression modules for COPD phenotypes. PLoS One. 2017;12:e0185682. doi:10.1371/journal.pone.0185682
   PubMed Web of Science ®Google Scholar
• ECLIPSE Investigators; Singh D, Fox SM, Tal-Singer R, et al. Induced sputum genes associated with spirometric and radiological disease severity in COPD ex-smokers. Thorax. 2011;66(6):489–495. doi:10.1136/thx.2010.153767.
   PubMed Web of Science ®Google Scholar
• Gupta V, Khan A, Higham A, et al. The effect of phosphatidylinositol-3 kinase inhibition on matrix metalloproteinase-9 and reactive oxygen species release from chronic obstructive pulmonary disease neutrophils. Int Immunopharmacol. 2016;35:155–162. doi:10.1016/j.intimp.2016.03.027
   PubMed Web of Science ®Google Scholar
• Pavord ID, Jones PW, Burgel PR, Rabe KF. Exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11(speciss):21–30. doi:10.2147/COPD.S85978
   PubMedGoogle Scholar
• Singh D, Fox SM, Tal-Singer R, Bates S, Riley JH, Celli B. Altered gene expression in blood and sputum in COPD frequent exacerbators in the ECLIPSE cohort. PLoS One. 2014;9(9):e107381. doi:10.1371/journal.pone.0107381
   PubMed Web of Science ®Google Scholar
• COPDMAP; Michaeloudes C, Kuo CH, Haji G, et al. Metabolic re-patterning in COPD airway smooth muscle cells. Eur Respir J. 2017;50:1700202. doi:10.1183/13993003.00202-2017
   PubMed Web of Science ®Google Scholar
• Ryter SW, Rosas IO, Owen CA, et al. Mitochondrial dysfunction as a pathogenic mediator of chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Ann Am Thorac Soc. 2018;15:S266–S272. doi:10.1513/AnnalsATS.201808-585MG
   PubMed Web of Science ®Google Scholar
• Cosio MG, Saetta M, Agusti A. Immunologic aspects of chronic obstructive pulmonary disease. N Engl J Med. 2009;360:2445–2454. doi:10.1056/NEJMra0804752
   PubMed Web of Science ®Google Scholar
• Remels AH, Gosker HR, Schrauwen P, Langen RC, Schols AM. Peroxisome proliferator-activated receptors: a therapeutic target in COPD? Eur Respir J. 2008;31:502–508. doi:10.1183/09031936.00068207
   PubMed Web of Science ®Google Scholar
• Wan ES, Silverman EK. Genetics of COPD and emphysema. Chest. 2009;136:859–866. doi:10.1378/chest.09-0555
   PubMed Web of Science ®Google Scholar
• Stolk J, Stockley RA, Stoel BC, et al. Randomised controlled trial for emphysema with a selective agonist of the γ-type retinoic acid receptor. Eur Respir J. 2012;40:306–312. doi:10.1183/09031936.00161911
   PubMed Web of Science ®Google Scholar
• Higham A, Lea S, Plumb J, et al. The role of the liver X receptor in chronic obstructive pulmonary disease. Respir Res. 2013;14:106. doi:10.1186/1465-9921-14-106
   PubMed Web of Science ®Google Scholar
• Criner RN, Han MK. COPD care in the 21st century: a public health priority. Respir Care. 2018;63:591–600. doi:10.4187/respcare.06276
   PubMed Web of Science ®Google Scholar